{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:50:21Z","timestamp":1791643821753,"version":"4.3.4"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014354","name":"Milstein Medical Asian American Partnership Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014354","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Bullous pemphigoid (BP) is the most common type of autoimmune bullous disease and is characterized by the presence of circulating anti-BP180 and\/or anti-BP230 autoantibodies. Patients with BP often present with tense blisters and erythema, mainly on the trunk and limbs, but a few patients also have mucosal involvement. In this article, we discuss the fact that BP patients with mucosal involvement tend to have more serious conditions and their disease is more difficult to control. Potential risk factors for mucous involvement include earlier age at onset, drugs such as dipeptidyl peptidase-4 inhibitors, cancer, and blood\/serum biomarkers, including lower eosinophil count, higher erythrocyte sedimentation rate, IgG autoantibodies against both the NH<jats:sub>2<\/jats:sub>- and COOH-termini of BP180, and the absence of anti-BP230 antibodies. IgA and C3 deposition at the dermo-epidermal junction may also be present. Understanding these risk factors may benefit earlier diagnosis of these patients and promote the development of novel treatments. What's more, it's helpful in deeper understanding of BP development and the relationship between BP and mucous membrane pemphigoid (MMP).<\/jats:p>","DOI":"10.3389\/fmed.2021.680871","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T04:46:15Z","timestamp":1621485975000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review"],"prefix":"10.3389","volume":"8","author":[{"given":"Xinyi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)."},{"key":"B2","volume-title":"Bullous Pemphigoid. StatPearls","author":"Baigrie","year":"2020"},{"key":"B3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"An Bras Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"10","author":"Tasanen","year":"2019","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/bjd.12072","article-title":"British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012","volume":"167","author":"Venning","year":"2012","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19890","article-title":"Mortality and clinical response of patients with bullous pemphigoid treated with rituximab","author":"Yoo","year":"2021","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.3389\/fimmu.2018.02687","article-title":"Complement-activating capacity of autoantibodies correlates with disease activity in bullous pemphigoid patients","volume":"9","author":"Chiorean","year":"2018","journal-title":"Front immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jdermsci.2017.07.012","article-title":"IgG4, complement, and the mechanisms of blister formation in pemphigus and bullous pemphigoid","volume":"88","author":"Dainichi","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00403-017-1736-1","article-title":"Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis","volume":"309","author":"Liu","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/1346-8138.13051","article-title":"Serum levels of immunoglobulins G1 and G4 targeting the non-collagenous 16A domain of BP180 reflect bullous pemphigoid activity and predict bad prognosis","volume":"43","author":"Zhou","year":"2016","journal-title":"J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/jamadermatol.2018.5049","article-title":"Assessment of the prevalence of mucosal involvement in bullous pemphigoid","volume":"155","author":"Kridin","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3389\/fimmu.2018.00479","article-title":"Mucosal involvement in bullous pemphigoid is mostly associated with disease severity and to absence of anti-bp230 autoantibody","volume":"9","author":"Clape","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3389\/fimmu.2018.00570","article-title":"Anti-type vii collagen antibodies are identified in a subpopulation of bullous pemphigoid patients with relapse","volume":"9","author":"Giusti","year":"2018","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S1085-5629(03)00083-X","article-title":"Subepidermal blistering disorders: a clinical and histopathologic review","volume":"23","author":"Kolanko","year":"2004","journal-title":"Semin Cutan Med Surg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jaut.2016.06.019","article-title":"IgG4 autoantibodies are inhibitory in the autoimmune disease bullous pemphigoid","volume":"73","author":"Zuo","year":"2016","journal-title":"J Autoimmun"},{"key":"B17","first-page":"E1","article-title":"Features of oral, pharyngeal, and laryngeal lesions in bullous pemphigoid","volume":"95","author":"Ohki","year":"2016","journal-title":"Ear Nose Throat J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.3389\/fimmu.2019.02219","article-title":"A retrospective study of patient-reported data of bullous pemphigoid and mucous membrane pemphigoid from a US-based registry","volume":"10","author":"Lee","year":"2019","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1046\/j.1365-2230.1997.d01-234.x","article-title":"Bullous pemphigoid evolving into cicatricial pemphigoid?","volume":"22","author":"Banfield","year":"1997","journal-title":"Clin Exp Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s40257-019-00461-7","article-title":"Oral lesions in autoimmune bullous diseases: an overview of clinical characteristics and diagnostic algorithm","volume":"20","author":"Rashid","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"631098","DOI":"10.1155\/2015\/631098","article-title":"A case of oropharyngeal bullous pemphigoid presenting with haemoptysis","volume":"2015","author":"Lee","year":"2015","journal-title":"Case Rep Otolaryngol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1365-2133.2012.11108.x","article-title":"Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort","volume":"167","author":"della Torre","year":"2012","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","article-title":"Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid","volume":"128","author":"Di Zenzo","year":"2008","journal-title":"Clin Immunol (Orlando, Fla)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40272-019-00349-3","article-title":"Bullous diseases in children: a review of clinical features and treatment options","volume":"21","author":"Schultz","year":"2019","journal-title":"Paediatr Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/ajd.12040","article-title":"A retrospective review of the therapeutic response with remission in patients with newly diagnosed bullous pemphigoid","volume":"55","author":"Chuah","year":"2014","journal-title":"Australas J Dermatol"},{"key":"B27","first-page":"243","article-title":"Association between immunofluorescence pattern and mucosal involvement in patients with bullous pemphigoid","volume":"26","author":"Eftekhari","year":"2018","journal-title":"Acta Dermatovenerol Croatica"},{"key":"B28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1046\/j.1365-2230.1999.00457.x","article-title":"Bullous pemphigoid: correlation of mucosal involvement and mucosal expression of autoantigens studied by indirect immunofluorescence and immunoblotting","volume":"24","author":"Kirtschig","year":"1999","journal-title":"Clin Exp Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: trigger and predisposing factors","volume":"10","author":"Moro","year":"2020","journal-title":"Biomolecules"},{"key":"B31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/bjd.15195","article-title":"The association between drugs and bullous pemphigoid","volume":"176","author":"Tan","year":"2017","journal-title":"Br J Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/jid.2008.424","article-title":"Plasmin plays a role in the in vitro generation of the linear IgA dermatosis antigen LADB97","volume":"129","author":"Hofmann","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/1346-8138.14245","article-title":"Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid","volume":"45","author":"Chijiwa","year":"2018","journal-title":"J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1111\/1346-8138.14237","article-title":"Case of bullous pemphigoid associated with teneligliptin accompanied by severe mucous membrane involvement","volume":"45","author":"Kage","year":"2018","journal-title":"J Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40257-020-00563-7","article-title":"More severe erosive phenotype despite lower circulating autoantibody levels in dipeptidyl peptidase-4 inhibitor (DPP4i)-associated bullous pemphigoid: a retrospective cohort study","volume":"22","author":"St\u00e4nder","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"adv00377","DOI":"10.2340\/00015555-3740","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature","volume":"101","author":"Tsiogka","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40257-016-0235-z","article-title":"Paraneoplastic pemphigus and autoimmune blistering diseases associated with neoplasm: characteristics, diagnosis, associated neoplasms, proposed pathogenesis, treatment","volume":"18","author":"Kartan","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/bjd.16679","article-title":"Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation","volume":"179","author":"Kridin","year":"2018","journal-title":"Br J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e107725","DOI":"10.1371\/journal.pone.0107725","article-title":"Human eosinophils express the high affinity IgE receptor, Fc\u03b5RI, in bullous pemphigoid","volume":"9","author":"Messingham","year":"2014","journal-title":"PLoS ONE"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.3389\/fimmu.2019.02331","article-title":"The intersection of IgE autoantibodies and eosinophilia in the pathogenesis of bullous pemphigoid","volume":"10","author":"Messingham","year":"2019","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/exd.13416","article-title":"Eosinophils as putative therapeutic targets in bullous pemphigoid","volume":"26","author":"Simon","year":"2017","journal-title":"Exp Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fmed.2018.00201","article-title":"The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease","volume":"5","author":"Amber","year":"2018","journal-title":"Front Med (Lausanne)."},{"key":"B45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1586\/1744666X.2016.1123092","article-title":"IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases","volume":"12","author":"van Beek","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijwd.2020.01.005","article-title":"Correlation of dermal and blood eosinophilia with bullous pemphigoid disease severity","volume":"6","author":"Farnaghi","year":"2020","journal-title":"Int J Womens Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/07853890.2018.1443346","article-title":"Relapse of bullous pemphigoid: an update on this stubborn clinical problem","volume":"50","author":"Wang","year":"2018","journal-title":"Ann Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00403-018-1817-9","article-title":"BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid","volume":"310","author":"Daneshpazhooh","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1046\/j.1523-1747.2002.19529.x","article-title":"Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain","volume":"119","author":"Hofmann","year":"2002","journal-title":"J Invest Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/bjd.18343","article-title":"A patient with bullous pemphigoid with mucosal involvement serologically positive for anti-BP230 autoantibodies only","volume":"182","author":"Taki","year":"2020","journal-title":"Br J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1365-2230.1986.tb00475.x","article-title":"Skin immunofluorescence in the diagnosis of primary bullous diseases\u2013a review of 279 cases","volume":"11","author":"Maurice","year":"1986","journal-title":"Clin Exp Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1046\/j.1365-2230.1999.00485.x","article-title":"IgA basement membrane zone autoantibodies in bullous pemphigoid detect epidermal antigens of 270-280 kDa, 230 kDa, and 180 kDa molecular weight by immunoblotting","volume":"24","author":"Kirtschig","year":"1999","journal-title":"Clin Exp Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/j.1365-2133.2011.10776.x","article-title":"Mucous membrane pemphigoid with generalized blisters: IgA and IgG autoantibodies target both laminin-332 and type XVII collagen","volume":"166","author":"Hayashi","year":"2012","journal-title":"Br J Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archdermatol.2007.9","article-title":"Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid","volume":"144","author":"Iwata","year":"2008","journal-title":"Arch Dermatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jdermsci.2004.10.007","article-title":"Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid","volume":"37","author":"Tsuji-Abe","year":"2005","journal-title":"J Dermatol Sci"},{"key":"B56","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1365-2133.2012.10820.x","article-title":"Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid","volume":"166","author":"Bl\u00f6cker","year":"2012","journal-title":"Br J Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5021\/ad.2012.24.1.45","article-title":"Usefulness of enzyme-linked immunosorbent assay using recombinant BP180 and BP230 for serodiagnosis and monitoring disease activity of bullous pemphigoid","volume":"24","author":"Lee","year":"2012","journal-title":"Ann Dermatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.12932\/AP-231118-0446","article-title":"Anti-BP180 and anti-BP230 enzyme-linked immunosorbent assays for diagnosis and disease activity tracking of bullous pemphigoid: a prospective cohort study","author":"Chanprapaph","year":"2019","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1749-6632.2009.04630.x","article-title":"Evaluation of a new ELISA assay for detection of BP230 autoantibodies in bullous pemphigoid","volume":"1173","author":"Tampoia","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jid.2018.03.002","article-title":"High expression of collagen XVII compensates for its depletion induced by pemphigoid IgG in the oral mucosa","volume":"138","author":"Kamaguchi","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/bjd.14351","article-title":"Salivary IgA and IgG antibodies to bullous pemphigoid 180 noncollagenous domain 16a as diagnostic biomarkers in mucous membrane pemphigoid","volume":"174","author":"Ali","year":"2016","journal-title":"Br J Dermatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.4049\/jimmunol.176.3.2015","article-title":"Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230","volume":"176","author":"Thoma-Uszynski","year":"2006","journal-title":"J Immunology (Baltimore, Md: 1950)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/jdv.15325","article-title":"Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid","volume":"33","author":"Zheng","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.680871\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T04:46:20Z","timestamp":1621485980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.680871\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":63,"alternative-id":["10.3389\/fmed.2021.680871"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.680871","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"article-number":"680871"}}